Maia Biotechnology, Inc., a Chicago IL-based immune-oncology company, raised $8.0m in funding.
The round was led by Checkmate Capital Group, BRK Financial Group, and MDL Investments.
The company intends to use the funds to advance its targeted immuno-oncology programs and initiate a Phase 1/2 clinical trial evaluating THIO followed by Libtayo® (cemiplimab) in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The Phase 1/2 clinical trial is expected to begin later this year.
Led by Vlad Vitoc, MD, Chief Executive Officer and President, Maia Biotechnology is a targeted therapy, immuno-oncology company focused on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Drug candidates include
(i) THIO, a first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells and
(ii) two compound families in pre-clinical evaluation for the treatment of prostate cancer and breast cancer using a potentially novel mode of action targeting androgen receptor (AR) and direct FKBP52 co-chaperone inhibition.